Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects

NCT03076385 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT03076385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03076385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2015
Completion date
October 31, 2018
Enrollment
201 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza